EX-32.2 5 exhibit_32-2.htm EXHIBIT 32.2
Exhibit 32.2
  
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
 
In connection with the quarterly report of Artemis Therapeutics, Inc., or the Company, on Form 10-Q for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, David Dana, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:
 
 
1.
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Dated: August 22, 2022
/s/ David Dana
 
David Dana
 
Chief Financial Officer
(Principal Financial Officer)